21 March 2024
BIOPHARMA
CREDIT PLC
("BIOPHARMA CREDIT" OR THE "COMPANY")
DIVIDEND
DECLARATION
BioPharma Credit PLC (LSE: BPCR),
the specialist life sciences debt investor, is pleased to declare
an interim dividend in respect of the financial period ending 31
March 2024 of $0.0175 per ordinary share, payable on 30 April 2024
to ordinary shareholders on the register as at 2 April 2024. The
ex-dividend date will be 28 March 2024. The Company has chosen to
designate the entire amount of this interim dividend as an interest
distribution. Shareholders in receipt of such a dividend will be
treated for UK tax purposes as though they have received a payment
of interest. This will result in a reduction in the corporation tax
payable by the Company.
The Company is currently paying and
continues to target a 7 cent annual dividend per ordinary
share.
The default payment for dividends is
in US dollars. However, shareholders can elect to have dividends
paid in sterling (GBP) and the option to elect a sterling dividend
payment for this dividend will be available to shareholders until 2
April 2024 (the "Election Date").
Further details together with a copy
of the Dividend Currency Election Form, which should be sent to
Link Group, 10th Floor, Central
Square, 29 Wellington Street, Leeds LS1 4DL when
completed, will be available on the Group's website shortly
at www.bpcruk.com/investor-materials.
CREST shareholders must elect via CREST. Further details together
with a copy of the Dividend Currency Election Form, which should be
sent to Link Group, 10th Floor, Central Square, 29
Wellington Street, Leeds LS1 4DL when completed, will be
available on the Group's website shortly
at www.bpcruk.com/investor-materials.
CREST shareholders must elect via CREST.
Enquiries:
BioPharma Credit plc
via Link Company Matters
Limited
Company Secretary
+44 (0) 333 300 1950
Buchanan
David Rydell / Mark Court
/ Jamie Hooper / Henry Wilson
+44 (0)20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's
only listed specialist investor in debt from the life sciences
industry and joined the LSE on 27 March 2017. The Company seeks to
provide long-term shareholder returns, principally in the form of
sustainable income distributions from exposure to the life sciences
industry. The Company seeks to achieve this objective primarily
through investments in debt assets secured by royalties or other
cash flows derived from the sales of approved life sciences
products.
LEI: 213800AV55PYXAS7SY24